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Translocation of silver nanoparticles in the ex vivo
human placenta perfusion model characterized by
single particle ICP-MS†
Janja Vidmar, a,b Katrin Loeschner, c Manuel Correia,c Erik H. Larsen,c
Pius Manser,d Adrian Wichser,d,e Kailen Boodhia,f Zahraa S. Al-Ahmady, g
Jaimé Ruiz,h Didier Astruc h and Tina Buerki-Thurnherr *d
With the extensive use of silver nanoparticles (AgNPs) in various consumer products their potential toxicity
is of great concern especially for highly sensitive population groups such as pregnant women and even
the developing fetus. To understand if AgNPs are taken up and cross the human placenta, we studied
their translocation and accumulation in the human ex vivo placenta perfusion model by single particle
ICP-MS (spICP-MS). The impact of diﬀerent surface modiﬁcations on placental transfer was assessed by
AgNPs with two diﬀerent modiﬁcations: polyethylene glycol (AgPEG NPs) and sodium carboxylate
(AgCOONa NPs). AgNPs and ionic Ag were detected in the fetal circulation in low but not negligible
amounts. Slightly higher Ag translocation across the placental barrier for perfusion with AgPEG NPs and
higher AgNP accumulation in placental tissue for perfusion with AgCOONa NPs were observed. Since
these AgNPs are soluble in water, we tried to distinguish between the translocation of dissolved and par-
ticulate Ag. Perfusion with AgNO3 revealed the formation of Ag containing NPs in both circulations over
time, of which the amount and their size in the fetal circulation were comparable to those from perfusion
experiments with both AgNP types. Although we were not able to clarify whether intact AgNPs and/or Ag
precipitates from dissolved Ag cross the placental barrier, our study highlights that uptake of Ag ions and/
or dissolution of AgNPs in the tissue followed by re-precipitation in the fetal circulation needs to be con-
sidered as an important pathway in studies of AgNP translocation across biological barriers.
Introduction
Silver nanoparticles (AgNPs) are, due to their antibacterial pro-
perties, one of the most widely used engineered NPs, and are
found in many commercial and medical products (e.g. food
packaging, textiles, laundry detergents, prosthetic devices,
dietary supplements, cosmetics). Humans may come into
contact with AgNPs either accidentally (e.g. through exposure
from contaminated drinking water, inhalation or by direct
skin contact) or intentionally (e.g. in the case of nanomedical
wound dressings or other applications).1 This raises concerns
about AgNP accumulation, long-term retention in an organism
and subsequent adverse health eﬀects. There is increasing
evidence for potential human toxicity of AgNPs2 and possible
mechanisms of AgNP toxicity have been described and include
their adverse eﬀects on cell membranes, mitochondria and
genetic material, causing induction of reactive oxygen species
(ROS), oxidative stress, genotoxicity and apoptosis.2–4
The growing fetus is particularly vulnerable to harmful
compounds even at concentrations that are non-toxic for
adults. Although the placenta provides a protective barrier for
the entry of harmful substances, previous studies have demon-
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strated that some NPs can pass the placental barrier and
induce pregnancy or fetal complications in pregnant
rodents.5–8 For AgNPs, no developmental toxicity has been
observed after repeated-dose oral administration in rats.9–11 In
contrast, exposure to AgNPs induced teratogenic eﬀects in
mice12–14 and aquatic species.15,16 For instance, pulmonary
exposure of pregnant mice to AgNPs induced an increased
number of resorbed fetuses14 or long-lasting impairment of
lung development of the oﬀspring.13 However, results from
animal experiments cannot directly be extrapolated to humans
due to substantial diﬀerences in placental development, struc-
ture and function among species.17,18 The most promising and
clinically relevant model for studying accumulation and trans-
port of substances across the human placenta is the ex vivo
human placental perfusion system developed by Panigel
et al.19 Although this model is increasingly being used to study
the transfer of diﬀerent NPs,20,21 no study with AgNPs has
been performed so far. The only available data on potential
transplacental transfer of AgNPs are from rodent studies,
where increased Ag concentrations were detected in fetal
organs.11,13,22–24 Recently, the visualization of AgNPs with
similar sizes as those of the applied AgNPs in the placenta and
fetal tissues has been interpreted as an indicator for placental
transfer of these particles.13 However, it is not yet clearly estab-
lished if Ag transfer occurs in particulate or ionic forms and
how diﬀerent AgNP properties and functionalizations aﬀect
placental barrier crossing.
In general, NP toxicity, cellular uptake or transfer across
biological barriers depend not only on particle concentration,
but also on their physicochemical properties,25 surface modifi-
cation, agglomeration26 and dissolution.27 Dissolution of
AgNPs, also in complex biological systems, has been widely
reported in the literature28 but there is a lack of consensus if
AgNP-mediated toxicity is driven by the particles per se, the
released Ag ions, or their combination.29 Some evidence that
the release of Ag ions from NPs is responsible for their toxic
eﬀects toward organisms has been provided by several studies
showing that AgNPs did not have bactericidal and cytotoxic
eﬀects when no dissolution of the NPs occurred28,30 or that
dissolved Ag had similar neurotoxic eﬀects as AgNPs.31
A common problem for the reliable quantification and
characterization of NPs under realistic exposure concen-
trations, where transfer rates are expected to be very low, is the
insuﬃcient limit of detection (LOD) of many analytical
methods (both in terms of NP concentration and size) as well
as problems related to matrix interferences and availability of
eﬃcient sample preparation methods.8,32 Inductively coupled
plasma-mass spectrometry in single particle mode (spICP-MS),
established by Degueldre et al.,33 has become a technique of
choice for studying metal-containing NPs in various matrices.
spICP-MS is capable of providing information on the number-
based particle size distribution and quantifying particle number
and mass concentration as well as mass concentration of the dis-
solved fraction of the element in question. In spICP-MS analysis,
a highly diluted suspension of NPs (particle mass concentrations
usually in the range of ng L−1) and use of short dwell times
(from a few hundred microseconds to a few milliseconds) are
required. Under ideal conditions, each recorded signal corres-
ponds to a single particle. The frequency of ICP-MS signals can
be used to determine the NP number concentration, while the
intensity of the signals is related to the mass of the detected
element in the NP and thus to its size under the assumption of a
spherical particle.34 Furthermore, spICP-MS does not require
demanding sample preparation for aqueous suspensions (only
dilution), while for NPs in tissue samples, appropriate digestion
procedures have to be applied.35,36
The goal of this study was the investigation of AgNP trans-
location across the human placental barrier in dependence of
negative or neutral surface modifications (COONa versus PEG).
Since AgNPs can dissolve, one of the aims was to investigate if
precipitation of AgNPs from Ag ions occurred. Perfusion
experiments were performed using the ex vivo human placenta
perfusion model, which for the first time enabled studying
translocation and accumulation of AgNPs in a human model.
Experimental section
Nanoparticles
AgNPs (AgPEG and AgCOONa NPs) were provided within the
EU FP7 Nanosolutions project (http://www.nanosolutionsfp7.
com). The AgNPs were custom-synthesized for the
Nanosolutions project to mimic commercial NPs in order to
provide a more realistic, real-life safety assessment. A detailed
description of the AgNP synthesis and characterization is pre-
sented in ESI.† AgNPs were provided as aqueous suspensions
with a particle mass concentration of 10 mg mL−1 in 50 mL
brown glass vials (as protection from ambient light).
Ex vivo human placental perfusion and sample collection
Placentas were obtained from uncomplicated term pregnan-
cies after caesarean section at the Cantonal Hospital or Klinik
Stephanshorn in St Gallen. Written informed consent was
obtained prior to delivery. The project was approved by the
local ethics committee (EKSG 10/078) and performed in
accordance with the principles of the Declaration of Helsinki.
The placenta perfusion experiments were performed on a
human ex vivo placenta perfusion model at the Swiss Federal
Laboratories for Materials Science and Technology (Empa) as
described previously.37–39 Criteria for a successful perfusions
were leak from fetal to maternal circulation of <4 ml h−1 and
stable pH (7.2–7.4). The perfusion medium (PM) was M199
tissue culture medium (Sigma, St Louis, MO, USA) diluted 1 : 2
with Earl’s buﬀer and supplemented with 1 g L−1 glucose
(Sigma, St Louis, MO, USA), 10 g L−1 bovine serum albumin
(AppliChem GmbH, Darmstadt, Germany), 10 g L−1 dextran 40
(Sigma, St Louis, MO, USA), 2500 IU L−1 sodium heparin
(B. Braun Medical AG, Melsungen, Germany), 250 mg L−1
amoxicillin (GlaxoSmithKline AG, Brentford, UK) and 2.2 g L−1
sodium bicarbonate (Merck, Darmstadt, Germany). Prior to
the experiments, AgNPs stock suspensions were gently mixed
by inverting the vial, diluted 250-times (AgPEG) or 135-times
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(AgCOONa) in PM and immediately used for placental per-
fusion studies. The resulting Ag mass concentrations for
AgPEG and AgCOONa NPs in the maternal circulation at the
start of the experiment were 12.48 µg mL−1 and 39.26 µg mL−1,
respectively, which corresponded to 40 µg mL−1 and
75 µg mL−1 of particle mass concentrations including coating,
respectively. The experiments were performed in triplicates
(N = 3) for each AgNP type. Maternal and fetal perfusates were
sampled in duplicate (experimental subsamples) after 0, 1, 3
and 6 h of perfusion. In order to assess possible precipitation
of insoluble silver salts as particles, perfusion with 1 µg mL−1
of ionic Ag (AgNO3) (N = 3) was performed. This concentration
was selected as the maximum amount of ionic Ag present in
the stock solution of AgNPs. Control perfusion with PM
without addition of AgNPs (N = 1) was also conducted to
examine the background levels of Ag.
In order to investigate the degree of AgNPs accumulation,
placental tissue samples from the villous chorion were col-
lected before (0 h) and after each perfusion experiment (after
6 h) and homogenized by mixing 2 g of tissue in 2 mL of per-
fusion buﬀer (dilution factor of 2). All samples for spICP-MS
analysis, i.e. perfusates and tissue homogenates, were immedi-
ately delivered to the Technical University of Denmark at 4 °C
and analyzed by spICP-MS within 3 days. A part of the repli-
cates (N = 1 for AgPEG NPs and N = 2 for AgNO3) were per-
formed one year later.
DLS measurements
Determination of hydrodynamic size and size distribution of
AgNPs in UPW (resistivity 18.2 mΩ cm−1), obtained from a
Millipore Element apparatus (Millipore, Milford, MA, USA)
and PM was performed by DLS (Zetasizer, Malvern
Instruments, UK). The measurements were carried out using
dust-free disposable cuvettes (DTS0012, Malvern Instruments,
UK). The measurement position was fixed at the center of the
cuvette (4.65 mm from the cuvette wall). The detection angle
was 173° and the measurement was performed at a tempera-
ture of 25 °C, which was achieved following equilibration for
1–2 minutes. Five consecutive measurements were performed
using a minimum of 11 runs of 10 s each. The results obtained
by DLS of the measured samples, given as Z-average (Zave) and
polydispersity index, were determined by averaging the results
of the five repeated measurements (N = 5) for one diluted
AgNPs suspension.
Enzymatic tissue digestion
For the enzymatic treatment of tissue, the enzyme solution
was prepared by diluting 3 mg mL−1 of Proteinase K (commer-
cial protease from Engyodontium album) and 0.5% (m/v)
sodium dodecyl sulphate (SDS, ReagentPlus with ≥98.5%
purity) in enzyme buﬀer, consisting of 50 mM ammonium
bicarbonate buﬀer (with 99% purity) and 200 µg mL−1 sodium
azide (with ≥98% purity), all purchased from Sigma-Aldrich
(St Louis, MO, USA) at pH 7.4 (PHM 240 pH/ION meter from
Radiometer, Copenhagen, Denmark). To allow double determi-
nations, each homogenated sample was divided into two sub-
samples before enzymatic treatment. A mass of 0.2 g of tissue
homogenate (corresponding to 0.1 g of wet tissue) was
weighed into plastic tubes with round bottom (Karter
Scientific Labware Manufacturing, Lake Charles, LA, USA).
After the addition of 2.0 mL of the enzyme solution (60 µg of
enzyme per mg of wet tissue) and 300 µL of UPW, samples
were shortly vortexed with a MS2 minishaker (IKA Works, Inc.,
Wilmington, NC, USA) until no sample adhered to the tube
walls. The samples were placed in the water bath at 37 °C
(HetoHMT 200 RS thermostat) and magnetically stirred with
the use of Telesystem HP15 magnetic stirrer (Holm & Halby,
Allerød, Denmark) for 1 h. At the end of enzymatic treatment,
the completely digested samples were placed in ice water to
slow down the enzymatic digestion process and appropriately
diluted with UPW prior to spICP-MS measurements.
spICP-MS analysis
A Thermo Scientific iCAP Q ICP-MS instrument (Thermo
Fisher Scientific GmbH, Bremen, Germany) was used for
single particle measurement of the samples from all the per-
fusion experiments with the following practical exceptions. For
the samples from one of the perfusion experiments with
AgCOONa NPs an Agilent 8800 Triple Quadrupole ICP-MS
instrument (Agilent Technologies, California, USA) was applied
and an Agilent 7900 ICP-MS instrument was used for measuring
the samples from one perfusion experiment with AgPEG NPs
and two perfusion experiments with AgNO3. Instrument tuning
was performed prior to analysis by using a tuning solution
according to the manufacturer’s recommendation. Settings for
all three instruments are given in Table S1.†
Accurate sample flow rate was determined daily by weigh-
ing. Quantification of particle size (particle diameter) was
based on a calibration curve constructed from a blank (UPW)
and four concentration levels of certified standard solutions of
Ag (1000 µg mL−1, PlasmaCAL, SCP Science, Baie D’Urfé, QC,
Canada) ranging from 0.2 to 2.0 ng mL−1. For each sample, the
isotope 107Ag was detected using 3 ms dwell time for a total
measurement time of 180–600 s (equivalent to 60 000–200 000
data points).
The recorded signal intensity data were plotted (in cps)
versus number of “events”, to create a signal distribution histo-
gram using Microsoft Excel (Microsoft, WA, USA). The
threshold between signals from instrumental noise/dissolved
Ag and particulate Ag was set to a value that gives a lowest
detectable particle diameter of 25 nm. This value corre-
sponded to the maximum of dissolved Ag concentration that
was found in the PM samples from the maternal side at time
0 h (i.e., up to 68 ng L−1 in diluted samples). Lower diameters
(down to 13 nm) could be detected in fetal perfusates and
maternal perfusates collected at longer perfusion times.
However, the application of the same threshold for all samples
ensured that a direct comparison of particle mass and number
concentrations as well as median particle diameters between
samples was possible. The Ag mass fraction below the selected
threshold was used to estimate the mass concentration of dis-
solved Ag and AgNPs smaller than 25 nm.
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The transport eﬃciency of the liquid NP samples through
the sample introduction system was determined according to
the “particle size” method40 with the use of reference gold
nanoparticle suspension (RM8012), obtained from the
National Institute for Science and Technology (NIST,
Gaithersburg, MD, USA) with a known average particle dia-
meter (27.6 ± 2.1 nm as determined by TEM) and gold mass
concentration (48.17 ± 0.33 µg g−1). This suspension, diluted
107-times with UPW, in combination with a calibration curve
made of dissolved Au standards (0, 0.5 and 1 ng mL−1)
(1000 µg mL−1 Au standard, PlasmaCAL from SCP Science,
Baie D’Urfé, QC, Canada) was used to determine the transport
eﬃciency of the NPs. With the use of AuNPs, a calibration
curve that relates the most common signal intensity to the
average particle mass was created. Then, a corresponding cali-
bration curve from the dissolved Au standards was constructed
by multiplying dissolved Au standard concentration by the
sample flow rate and the dwell time to calculate the total Au
mass. Finally, the ratio of the slope from the calibration curve
made from the ionic Au standards and the slope from the cali-
bration curve created from the AuNPs was used to determine
the transport eﬃciency. To assess the accuracy of the transport
eﬃciency determined by the “particle size” method with the
use of AuNPs, the “particle frequency” method40 using 40 nm
AgPEG NPs (NanoXact Silver Nanospheres, purchased from
Nanocomposix, San Diego, CA, USA) was applied. There was no
significant diﬀerence in the so determined transport eﬃcien-
cies. For the validation of the spICP-MS method, the particle
number concentration of 40 nm AgPEG NPs (Nanocomposix)
was determined and compared to the expected particle number
concentration (calculated from the size provided by TEM and
Ag mass concentration provided by ICP-MS), where 95 ± 1%
(N = 2) recovery was achieved. Complete ionization of AgNPs
was confirmed by the comparable Ag concentrations observed
for the digested (i.e., dissolved) AgCOONa NPs (determined by
conventional ICP-MS) and undigested AgCOONa NPs (deter-
mined by spICP-MS) (Fig. S1†).
To prevent AgNPs from sticking to the ICP-MS tubings and
to avoid a memory eﬀect during ICP-MS measurements, the fol-
lowing washing procedure was applied after each sample: (1) 1%
(v/v) HCl (34–37%), 1% (v/v) HNO3 (67–69%), both of
PlasmaPURE quality, and 0.1% (m/v) Triton X-100 (Merck,
Darmstadt, Germany) for 1 min at 1.5 mL min−1, (2) UPW for 30
s at 1 mL min−1. Following the analysis of each sample, UPW was
aspirated into the ICP-MS for additional rinsing and to ensure
that no carryover from the previous measurement was detectable.
Prior to spICP-MS analysis, two (analytical) subsamples
were taken from each experimental subsample of perfusate
and diluted with ultrapure water (UPW). The list of analyzed
samples together with suitable dilution factors and total
measurement times, which were determined experimentally,
are presented in Table S2.† For the sake of counting statistics,
a minimum number of 400 particles were detected per sample
and the ratio between detected particles and number of dwells
restricted to a maximum of 20% to limit the probability of
multiple particle events during one dwell to 10%. The results
for the translocation experiments are expressed as Ag mass
concentration in perfusates normalized to the Ag mass concen-
tration measured on the maternal side at time 0 h (M0). Ag
mass concentrations determined in placental tissues, collected
before the start of perfusion, were subtracted from the Ag
values determined in tissues after 6 h of perfusion. Results
were expressed as Ag mass concentrations in the tissues that
were normalized to the applied Ag dose, measured in M0
samples by conventional ICP-MS, taking into account the total
mass of the placenta tissue and the total volume of perfusate.
Since there was not enough MO sample (maternal perfusate
after 0 min of perfusion) left from one of the perfusion with
AgCOONa NPs for conventional ICP-MS analysis, M15 sample,
collected shortly after the beginning of perfusion (15 min),
was used to estimate the starting concentration. This might
lead to a slight underestimation of the tissue concentration,
however, the error is likely smaller than the biological
variations observed between the individual experiments.
Behavior of AgNPs in perfusion medium
For studying aggregation of AgNPs in PM by DLS and
spICP-MS, AgPEG and AgCOONa NPs stock suspensions were
diluted in UPW or PM 5- and 10-times, respectively, (in case of
DLS analysis) and 125- and 1000-times, respectively (in case of
spICP-MS analysis). In order to assess if Ag ions could precipi-
tate as NPs in PM, diﬀerent concentrations of ionic Ag
(100 µg mL−1, 10 µg mL−1 and 1 µg mL−1) were prepared in
PM and their size distributions measured by DLS immediately
after their preparation and 4 days later after storage at room
temperature (RT). spICP-MS was applied for detecting possible
formation of Ag precipitates in PM in the lower concentration
range (4, 2 and 0.2 µg mL−1), over a period of 3 days at RT.
Prior to spICP-MS analysis (3 min measurement time),
samples containing 4, 2 and 0.2 µg mL−1 ionic Ag were diluted
4000, 2000 and 200-times, respectively. PM was diluted in the
same way and measured after each sample.
Statistical analysis
Results based on repeated measurements are given as mean ±
one standard deviation (STD). The number of repetitions N is
stated in parentheses. Data (comparison of quantiles of par-
ticle size distributions at diﬀerent perfusion times, repeatabil-
ity and reproducibility for sizing and quantification of AgNPs)
were statistically analyzed by using one-way Analysis of
Variance (ANOVA) in Microsoft Oﬃce Excel 2010 (Microsoft,
Redmond, WA, USA). A p-value ≤ 0.01 was considered statisti-
cally significant.
Results and discussion
Characterization of AgNPs
The basic characteristics for the stock suspensions of both
AgNP types, including total Ag mass concentration, mass frac-
tion of dissolved Ag, mass fraction of surface modification,
primary particle size and zeta potential are presented in
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Table 1. Besides revealing primary particle size, TEM analysis
further showed that AgPEG suspension contained three popu-
lations¨ -Ag spheres of 2–8 nm, Ag spheres close to 7–15 nm,
and a third minor population of large and irregular particles
in the 200–1000 nm size range. The AgCOONa NP suspensions
comprised, besides the primary particles, large assemblies of
100–500 nm containing multiple individual Ag spheres of
5–15 nm (Fig. S2†).
All NPs have been tested for endotoxin contamination and
were endotoxin free (<0.5 EU mL−1 in Chromogenic LAL assay).
Stability of AgNPs in perfusion medium
In order to assess if AgNPs aggregated/agglomerated in PM,
hydrodynamic size and size distribution of AgNPs in UPW and
PM were determined by DLS (Fig. 1). Size distributions
obtained for AgPEG and AgCOONa NPs in UPW were in agree-
ment with the TEM results (Fig. S2†). For AgPEG NPs in PM, a
slightly broader size distribution was observed in comparison
to UPW. Size distribution for pure PM (peaks around 10 nm
and 500 nm – data not shown) indicated that the size distri-
butions of AgNPs in PM can be attributed to the AgNPs and
not to scattering entities in the PM. For AgCOOH NPs in PM,
the size distribution shifted to significantly larger sizes with
the peak maximum at 1000 nm due to agglomeration/aggrega-
tion of the NPs.
Agglomeration/aggregation of AgCOONa NPs in PM was
further confirmed by spICP-MS measurements (Table 2 and
Fig. 2). While size distributions and mass concentrations of
AgPEG NPs were similar in UPW and PM, AgCOONa NPs aggre-
gated/agglomerated in PM resulting in bigger median dia-
meters, higher mass concentration of AgNPs >25 nm and
lower mass concentration of AgNPs ≤25 nm in comparison to
UPW.
Fig. 1 DLS hydrodynamic size measurements of AgNPs dispersed in
ultrapure water or perfusion medium. Intensity-based size distributions
of AgPEG (left) and AgCOONa NPs (right), dispersed in ultrapure water
(UPW) or perfusion medium (PM) at Ag mass concentration of approxi-
mately 0.3 mg mL−1. The data is representative of ﬁve (N = 5) consecu-
tive DLS measurements for each AgNPs type and media.
Table 1 Summary of AgNP stock suspension characteristics
AgNP characteristic AgPEG AgCOONa
Ag mass concentration (mg mL−1) 3.12 ± 0.06 5.30 ± 0.01
Mass fraction of dissolved Ag (w/w %) 4.9 ± 0.1 0.11 ± 0.01
Mass fraction of surface modification (w/w %) 64.1 16.3
Primary particle diameter (nm) 2–15 5–15
Zeta potential at pH 5 in UPW (mV) −10.7 ± 0.4 −32.5 ± 1.1
Results for Ag mass concentration (N = 3), mass fraction of dissolved
Ag (N = 2) and zeta potential (N = 5) are presented as mean ± STD.
Table 2 Mass concentrations and median diameters of AgNPs, dispersed in UPW and PM, determined by spICP-MS. Results present mean values ±
STD from two replicates
AgNP
type Medium
Expected Ag mass
conc.a (µg mL−1)
Mass conc. of
AgNPs >25 nm
(µg mL−1)
Mass conc. of AgNPs
≤25 nm + Ag ions
(µg mL−1)
Mass fraction of
AgNPs >25 nmb (%)
Ag mass
recoveryc (%)
Median particle
diameter (nm)
AgPEG UPW 12.5 0.141 ± 0.004 9.05 ± 0.24 1.5 73.6 27.7 ± 0.3
PM 0.121 ± 0.004 8.98 ± 0.14 1.3 72.9 27.4 ± 0.3
AgCOONa UPW 39.3 13.5 ± 0.3 17.0 ± 0.7 44 77.6 34.3 ± 0.3
PM 29.1 ± 2.0 7.65 ± 0.31 79 93.6 40.8 ± 0.4
a Based on ICP-MS analysis of digested stock suspensions. b Based on the total Ag mass concentration determined by spICP-MS (≤25 nm +
>25 nm). c Ag mass concentration (≤25 nm + >25 nm) determined by spICP-MS in comparison to the Ag mass concentration determined by con-
ventional ICP-MS after acid digestion.
Fig. 2 Size distributions of AgPEG NPs and AgCOONa NPs, dispersed in
ultrapure water or perfusion medium. The minimum detectable size by
spICP-MS was 25 nm. In case of AgCOONa NPs in perfusion medium,
NPs up to 270 nm nm were detected. Size distributions are representa-
tive of two replicates for each medium and each AgNP type.
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Translocation of Ag across the human placental barrier
40 µg ml−1 AgPEG NPs (12.5 µg ml−1 Ag) or 74 µg ml−1
AgCOONa (39 µg ml−1 Ag) were added to the maternal circula-
tion in an ex vivo placenta perfusion model, and changes of Ag
mass concentrations of the fraction >25 nm and the fraction
≤25 nm (AgNPs ≤25 nm and dissolved Ag) were followed over
the time of perfusion in maternal and fetal circulations by
spICP-MS (Fig. 3). AgPEG NPs and AgCOONa NPs were selected
as AgNPs with neutral and negatively charged surface modifi-
cations, respectively, since studies showed that cellular uptake
and translocation of negatively charged NPs is less likely to
occur compared to neutral or positively charged NPs.20,41–43
The concentrations of AgNPs were chosen as doses that were
non-toxic to BeWo trophoblast cells after 6 h of exposure
according to an MTS viability assay (Fig. S8†) but still relatively
high to be able to detect particle uptake and/or translocation
and to mimic a potential worst-case exposure scenario.
After perfusion with AgCOONa or AgPEG NPs, Ag mass frac-
tion > and ≤25 nm in the fetal circulation increased with time
of perfusion but overall, only very low amounts of the mater-
nally applied Ag doses were detected on the fetal side (Fig. 3).
The mass percentage of Ag fraction >25 nm that crossed the
placental barrier after 6 h of perfusion was 0.0148 ± 0.0192%
for AgPEG NPs (N = 3) and 0.0002 ± 0.0002% for AgCOONa
NPs (N = 3). However, the highest placental translocation was
not observed for the AgNPs > 25 nm but for the small AgNPs
and/or Ag ions (fraction ≤25 nm) with 0.1578 ± 0.1032% for
AgPEG NPs and 0.0151 ± 0.0077% for AgCOONa NPs. On the
maternal side, the Ag fraction >25 nm remained constant,
while the Ag fraction ≤25 nm decreased by 44% during 6 h of
perfusion in case of AgPEG NPs. In the case of AgCOONa NPs,
a strong decrease of both fractions was observed on the
maternal side during the 6 h of perfusion (63% decrease for
Ag fraction >25 nm and 13% decrease for Ag fraction ≤25 nm).
In addition to quantifying the Ag mass concentrations of
diﬀerent size fractions, spICP-MS analysis was also applied to
obtain information about the (number-based) particle size dis-
tribution on the maternal side over increasing time of per-
fusion and on the fetal side at the end of perfusion (Fig. 4).
For quantitative comparison of the particle size distribution
the 2.5, 50 and 97.5% percentiles of the size distributions were
calculated.
For perfusion experiments with AgCOONa NPs, smaller par-
ticles were present in the fetal circulation at the end of per-
fusion (median particle diameter (MPD) 27.4 ± 0.6 nm) as
compared to the maternal side at the beginning of perfusion
(MPD 32.8 ± 0.5 nm). In contrast, there was no significant
diﬀerence in the particle size distribution of AgPEG NPs
between maternal (MPD 27.5 ± 0.3 nm) and fetal side (MPD
28.7 ± 1.1 nm). In case of AgPEG NPs, a statistically significant
shift (p < 0.01) for all three percentile values of particle size
distribution towards larger particles occurred with time on the
maternal side (MPD 29.0 ± 0.1 nm after 6 h of perfusion) and
reached a size similar to the one observed on the fetal side at
the end of the perfusion. For AgCOONa NPs a statistically sig-
nificant decrease of the particle size with perfusion time was
Fig. 3 Perfusion proﬁles of AgPEG and AgCOONa NPs during ex vivo
human placental perfusion. Ag mass fraction >25 nm (continuous line)
and ≤25 nm (dashed line) were measured on the maternal (black color)
and fetal side (gray color) over a time period of 6 h by spICP-MS. Missing
points present non-detectable concentrations (<LOD). Data represent
the mean ± STD of the independent experiments (N = 3 for AgPEG NPs,
N = 3 for AgCOONa NP).
Fig. 4 Size distributions of AgNPs formed in perfusion with AgPEG and
AgCOONa NPs over time and determined by spICP-MS. Missing points
present non-detectable concentrations (<LOD). Data represent
the mean ± STD of the independent experiments (N = 3 for AgPEG NPs,
N = 3 for AgCOONa NP).
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observed (significant only for 50% percentile value) to a size of
30.8 ± 0.1 nm (MPD) on the maternal side after 6 h of
perfusion.
To confirm the results obtained by spICP-MS total Ag mass
concentrations on the maternal and fetal side for varying time
of perfusion were also determined by conventional ICP-MS
analysis and compared to the results obtained by spICP-MS
(Ag mass fraction > + ≤25 nm, the latter includes also the dis-
solved Ag fraction) (Fig. S1†). There was no significant diﬀer-
ence (t-test, p < 0.01) between the Ag concentrations deter-
mined by both methods for the perfusion studies with
AgCOONa NPs. However, in case of AgPEG NPs, about 3-times
higher Ag concentrations were detected in the maternal perfu-
sates at time 0 h by ICP-MS compared to spICP-MS. This indi-
cates unforeseen Ag mass losses during the spICP-MS
measurements. We suspect that the surface properties (PEG
coating) led to partial adhesion to the tubings of the sample
introduction system of the ICP-MS. However, the recoveries
were more favorable (73%) for AgPEG NPs freshly spiked to PM
(Table 2). Nevertheless, reduced spICP-MS recoveries of AgPEG
NPs do not have an impact on the obtained results, as relative
changes were investigated. The percentage of total Ag that
crossed the placental barrier (measured on the fetal side after
6 h of perfusion) was 0.0239 ± 0.0197% for AgCOONa and
0.0620 ± 0.0454% for AgPEG NPs when determined by conven-
tional ICP-MS and 0.0152 ± 0.0080% for AgCOONa and 0.0615 ±
0.0482% for AgPEG NPs when determined by spICP-MS.
Accumulation of Ag in the placental tissue
Although placental Ag transfer was very low, Ag mass concen-
tration in the maternal circulation was declining, in particular
for AgCOONa NPs (Fig. 3). In order to investigate the degree of
Ag accumulation in the placenta, tissue samples were enzy-
matically treated to release AgNPs and dissolved Ag from the
tissue. Ag mass fraction > and ≤25 nm were measured in pla-
cental tissues after 6 h of perfusion with AgPEG NPs and
AgCOONa NPs (Fig. 5).
For AgCOONa NPs, a much higher Ag fraction >25 nm of
the applied dose accumulate in the placenta (4.2%) as com-
pared to AgPEG NPs (0.75%), while the mass concentration of
the Ag fraction ≤25 nm was 7.5% for AgCOONa NP and 15%
for AgPEG. Overall, Ag mass fraction ≤25 nm represented 95%
and 64% of the total internalized Ag mass concentration
(≤25 nm + >25 nm) for AgPEG and AgCOONa NPs, respectively.
The amount of Ag determined in the placental tissue was
therefore much higher in comparison to the translocated Ag
(below 0.02% of Ag NPs >25 nm for both AgNP types),
suggesting that the transfer of Ag to the fetal circulation was
substantially hindered by the placental barrier. Strong
accumulation of Ag fraction >25 nm in the placental tissue
after the perfusion with AgCOONa NPs was reflected also
through the decrease of the Ag concentration on the maternal
side over time (Fig. 3). A possible explanation for the high Ag
concentrations in placenta may be the presence of high levels
of the metal-binding protein metallothionein in this tissue.44
The strong accumulation of Ag in the placental tissue is of
potential threat to the developing fetus if it interferes with
proper placental development and function or the release of
mediators (e.g. inflammatory, angiogenic or endocrine factors)
from placental tissue. Such indirect toxicity has been pre-
viously described in rodent and human in vitro placental trans-
fer studies for CoCr NPs.25,45,46 Although we did not directly
investigate the impact of Ag on placental tissue viability and
functionality, the maintenance of barrier integrity throughout
the perfusion experiments suggests the absence of major acute
toxicity to the placenta. However, further studies would be
required to understand the long-term consequences of high Ag
tissue levels on placental function. In addition, even if placen-
tal transfer of Ag is low, direct teratogenic eﬀects may occur
from translocated Ag in particular for a chronic exposure scen-
ario since the fetus is particularly vulnerable to toxic com-
pounds already at low levels. Previous studies with pregnant
rodents revealed that AgNPs may cause adverse eﬀects on
embryo’s health.13,47 Moreover, there is recent evidence that
AgNPs cause developmental neurotoxicity in human embryo-
nic neural precursor/stem cells in vitro.48,49
When comparing the sizes of AgNPs determined on the
maternal and fetal side after 6 h of perfusion with AgCOONa
NPs with those in placental tissue (Fig. 6), we observed larger
Ag particles (aggregates/agglomerates) on the maternal side
and in the placental tissue compared to the smaller particles
on the fetal side. In case of AgPEG NPs, there was no diﬀer-
ence in MPDs on the maternal side, in placental tissue and on
the fetal side.
The presence and localization of AgNPs in placental tissue
after 6 h of perfusion with AgPEG and AgCOONa NPs was also
assessed by CytoViva dark field microscopy (Fig. S4†). The
technique has the ability to detect a broad range of diﬀerently
sized NPs (from small monodispersed NPs50 up to large NP or
NP agglomerates/aggregates51) and to distinguish between NP
types if spectral profiles are suﬃciently distinct.50 Particulates
Fig. 5 Ag mass concentrations in placental tissues from perfusion
experiment with AgPEG and AgCOONa NPs. Ag mass fraction > and
≤25 nm were determined by spICP-MS in enzymatically treated tissue
samples. Ag mass concentrations in placenta collected after 6 h of per-
fusion are normalized to the applied Ag concentration measured in M0
samples (initial concentrations in maternal perfusates) by conventional
ICP-MS. Data represent the mean ± STD of the independent experi-
ments (N = 3 for AgPEG NPs, N = 3 for AgCOONa NPs).
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were observed in all perfused tissues and were mainly localized
in the syncytiotrophoblast layer. Particulates were neither
detected in control samples of placental tissue perfused with
perfusion medium only nor in placental tissue sections taken
before perfusion with AgNPs. To further verify the specificity of
the Ag signals, scans were also performed on AgNP suspensions
alone to generate spectral libraries, which were then mapped
onto the scans of the NP-perfused tissues using the image classi-
fication algorithm, spectral angle mapper (Fig. S5 and S6†).
Positive signals of particulate Ag were identified but an unam-
biguous identification of all AgNP signals was not possible since
the spectral profile of the particles changed in the tissue as com-
pared to the spectral library of the NPs in stock solution.
Translocation of dissolved Ag and formation of Ag containing
particles
Since AgNPs are soluble, one objective of the study was to dis-
tinguish between the translocation and uptake of dissolved
and particulate Ag in the ex vivo placenta perfusion model. In
our experiments with AgNPs, dissolved Ag was present on the
maternal or fetal side either due to particle dissolution in PM
during the perfusion experiment or due to the dissolved Ag
fraction that was already present in the AgNP suspensions
(4.9% for AgPEG and 0.11% for AgCOONa NP suspensions –
Table 1) or both. Loza et al.28 have shown that the predomi-
nant species formed from dissolved Ag in biological media in
the presence of chloride ions is colloidally dispersed nanopar-
ticulate AgCl, whereas in tissues ionic Ag typically deposits as
selenium and/or sulfur containing particles.52 We therefore
assumed that AgCl precipitation from dissolved Ag would
occur in the used PM. In order to study potential de novo for-
mation of Ag containing NPs from ionic Ag during the per-
fusion experiment, DLS and spICP-MS analyses for diﬀerent
concentrations of ionic Ag in PM were performed. AgNP pre-
cipitation in PM (additional peak in the size distribution with
a peak maximum at around 100–200 nm) was only detectable
by DLS when the ionic Ag concentration was 10 µg mL−1 or
higher (Fig. S7†). Even after prolonged incubation (4 days at
RT), no Ag particle formation was evident at relevant concen-
trations of dissolved Ag (1 µg mL−1) (data not shown), most
probably because DLS is not sensitive enough to detect NP for-
mation at such small concentrations. No Ag-containing NPs
could be detected even by the more sensitive spICP-MS
method in PM spiked with 2 or 4 µg mL−1 ionic Ag (2000- and
4000-times diluted prior to analysis, respectively) (data not
shown). In PM spiked with 0.2 µg mL−1 a very low number of
NPs (92) was detected. A similar number (108) was, however,
observed in the corresponding blank sample (200-times
diluted PM) indicating that less diluted PM has a stronger
ability to wash out AgNPs, adhered to ICP-MS tubes from pre-
vious measurements. Therefore, the particles detected in a
freshly prepared 0.2 µg mL−1 ionic Ag sample solution are
most probably the consequence of the particles wash-out
rather than formation of AgNPs in PM. No Ag-containing NPs
could be detected after 3 days incubation at RT either (data not
shown). In summary, at experimentally ionic Ag concen-
trations of 0.2 to 4 µg mL−1 no formation of Ag-containing NPs
was observed. The minimum detectable particle size in all
experiments with dissolved Ag was higher than in ex vivo per-
fusion experiments (approximately 47 nm) due to the lower
degree of dilution of samples prior to spICP-MS analysis. A
possible formation of particles smaller than this size cannot
be excluded. By performing a perfusion experiment with dis-
solved Ag, we wanted to assess if the dissolved Ag was able to
cross the placental barrier and if any Ag-containing NPs could
form from the dissolved Ag in the presence of PM and placen-
tal tissue.28,53,54 After perfusion with 1 µg mL−1 AgNO3
(Fig. 7A), an increase of the Ag mass fraction ≤25 nm was
measured in the fetal circulation over time by spICP-MS.
Interestingly, Ag particles >25 nm appeared in the maternal
circulation (already at time 0 h) and their concentration
increased gradually throughout the course of a perfusion
experiment. A significant number of particles was formed on
the maternal ((2.89 ± 1.23) × 107 particles per mL) and fetal
side ((1.10 ± 0.37) × 105 particles per mL) after 6 h of perfusion
(N = 3). The mass concentration of AgNP >25 nm on the fetal
side was 0.0165 ± 0.0070 µg L−1 after 6 h of perfusion (Fig. 7A).
This value was in the same concentration range as the mass
concentration of AgNPs >25 nm that was observed on the fetal
side after perfusion with AgNPs (0.819 ± 1.074 µg L−1 for
AgPEG (N = 3) and 0.081 ± 0.071 µg L−1 for AgCOONa (N = 3))
(Fig. 3). The size distribution of the newly precipitated par-
ticles on the fetal side after 6 h (MPD 26.1 ± 0.4 nm) was
similar to the size distribution of particles detected on the
fetal side after AgPEG (MPD 28.7 ± 1.1 nm) or AgCOONa NPs
(MPD 27.4 ± 0.6 nm) were added (Fig. S3A†). Moreover, the
Fig. 6 Size distributions of AgPEG and AgCOONa NPs on maternal,
fetal side and in placental tissue. Size distributions were determined by
spICP-MS after 6 h of perfusion and are representative of three indepen-
dent perfusion experiments (N = 3 for AgPEG NPs, AgCOONa NPs and
AgNO3).
Nanoscale Paper
This journal is © The Royal Society of Chemistry 2018 Nanoscale, 2018, 10, 11980–11991 | 11987
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
Ju
ne
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
1/
2/
20
18
 1
0:
43
:5
1 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
particle size on the maternal side increased with time of per-
fusion and larger particles were observed on the maternal side
(MPD 31.9 ± 1.5 nm) compared to the fetal side (MPD 26.1 ±
0.4 nm) after 6 h of perfusion (Fig. 7B and Fig. S3B†). Finally,
spICP-MS analysis revealed that predominantly Ag ions and/or
small AgNPs were taken up by the placental tissue (18% for
fraction ≤25 nm, 0.02% for AgNPs >25 nm) (Fig. 7C) and parti-
culates similar to the ones observed after perfusion with
AgNPs (Fig. S4†) were observed in placental tissue sections by
CytoViva dark field microscopy (Fig. 7D).
The concentrations and size distributions of the particles
detected on the fetal side after the addition of dissolved Ag
were comparable to those from the AgNP perfusion experi-
ments. The exact composition of the formed NPs could not be
determined with spICP-MS, because only one element per par-
ticle could be detected. Since no particle formation was
observed in PM, which contained relevant ionic Ag concen-
trations, the formation of NPs cannot be explained with inter-
action of Ag ions and PM only, but occurred most probably
due to the presence of proteins in the placental tissue. For
instance, amino acids containing thiol groups (i.e. cysteine)
have a high aﬃnity for ionic Ag, forming Ag(I)–sulfide com-
plexes.55 Bolea et al.56 substantiated this by showing that
association of dissolved Ag released from AgNPs with the pro-
teins is accelerated in the presence of cells.
Consequently, the observed presence of NPs in the fetal cir-
culation in ex vivo perfusion experiments with AgNPs could
therefore be either the result of the translocation of the pris-
tine AgNPs (scenario 1) or be caused by the translocation and
subsequent reduction or reaction with available ligands of dis-
solved Ag (originating from AgNPs dissolution) (scenario 2).
With the use of the spICP-MS method that provides infor-
mation only about particle size and not about the complete
particle composition we were not able to unambiguously
confirm the exact mechanism. Assuming the first scenario,
quantitatively diﬀerent degrees of Ag translocation of AgPEG
NPs and AgCOONa NPs across the placenta could be explained
by their diﬀerent size distributions in PM as a result of
diﬀerent surface modifications: AgCOONa NPs formed large
agglomerates/aggregates in the micrometer size range in PM.
In contrast, the size distribution of AgPEG NPs was not signifi-
cantly changed in PM (Table 2, Fig. 1). The higher degree of
agglomeration/aggregation observed for AgCOONa NPs in PM
could be attributed to the carboxylate groups which become
less ionized at high ionic strength in PM. The repulsive forces
between AgCOONa NPs are thereby weakened, leading to par-
ticle aggregation. PEG coating, on the other hand, provides
strong steric stabilization for the AgPEG NPs even in solution
with high ionic strength. Since agglomeration of NPs is
expected to significantly reduce placental transfer,20,37 a
Fig. 7 Characteristics of AgNO3 in perfusates and placental tissues during the perfusion experiment. (A) Perfusion proﬁles of dissolved Ag during
ex vivo human placental perfusion determined by spICP-MS. Ag mass fraction >25 nm (continuous line) and ≤25 nm (dashed line) were measured on
the maternal (black color) and fetal side (gray color) over a time period of 6 h. Missing points present non-detectable concentrations (<LOD). Data
represent the mean ± STD of three independent perfusion experiments (N = 3). (B) Size distributions of AgNPs formed in perfusion with dissolved Ag
over time, determined by spICP-MS. Missing points present non-detectable concentrations (<LOD). Data represent the mean ± STD of three inde-
pendent perfusion experiments (N = 3). (C) Ag mass concentrations in placental tissues from a perfusion experiment with AgNO3. Ag mass fraction
>and ≤25 nm were determined by spICP-MS in enzymatically treated tissue samples. Ag mass concentrations in placenta collected after 6 h of per-
fusion are normalized to the applied Ag concentration measured in M0 samples (initial concentrations in maternal perfusates) by conventional
ICP-MS. Data represent the mean ± STD of three independent perfusion experiments (N = 3). (D) Dark-ﬁeld images of placental tissue perfused with
AgNO3. Dark-ﬁeld images assessed by CytoViva dark ﬁeld microscopy were captured at 60× magniﬁcation of placental tissue before perfusion (0 h)
or after 6 h of perfusion. Scale bar represents 15 µm.
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higher dose of AgCOONa NPs compared to AgPEG NPs was
applied to the maternal circulation. However, even at higher
initial concentrations in the PM, the percentage of AgNPs in
fetal perfusates was lower for AgCOONa than for AgPEG NPs.
To conclude, the influence of NP surface charge/modification
on translocation could not be studied as a single factor as it
also aﬀected the agglomeration of NPs in perfusion medium
and consequently the size distribution.
NP size has been shown to be a key determinant in placen-
tal transfer with lower transfer for larger NPs.20 Further evi-
dence that size is the key determinant for AgNP translocation
was reflected in a more eﬃcient translocation of small AgNPs/
ionic silver (Ag fraction ≤25 nm) across the placental barrier
than larger AgNPs. Moreover, the comparison of particle size
distributions on the maternal and fetal side after 6 h of per-
fusion showed that smaller AgCOONa were present on the fetal
side (up to 96 nm) in comparison to the maternal side (NPs/
aggregates up to 230 nm) and the particles accumulated in pla-
cental tissue (up to 140 nm). Assuming the second scenario
(translocation of dissolved Ag followed by Ag reduction or reac-
tion with available ligands), the higher translocation of Ag in
case of AgPEG NPs in comparison to AgCOONa NPs could be
explained with the larger mass fraction of dissolved Ag of 4.9%
in comparison to 0.1% in the NP formulations and/or poten-
tially higher solubility of AgPEG NPs.
HSI analysis indicated that the NPs detected in placental
tissue were (at least to some extent) the pristine AgNPs, which
means that complete dissolution of the AgNPs on the maternal
side can be excluded. The finding does, however, not allow to
conclude that pristine AgNPs translocated to the fetal side.
In summary, our study demonstrates that the derivatised
AgNPs underwent complex reactions in the conducted trans-
location studies due to their readily soluble nature and their
chemical reactivity. In order to distinguish between transloca-
tion of intact AgNPs and that of dissolved Ag/ions originating
from the NPs further studies are needed, where other methods
for determining chemical composition of translocated AgNPs
(e.g. energy dispersive X-ray spectroscopy52,57) are required.
Another possibility would be isotope labeling in combination
with conventional ICP-MS, which however can suﬀer from the
risk of artificial and/or false-positive results associated with
labeled materials (e.g. loss of label and changes in NP pro-
perties and biointeractions). Moreover, distinguishing between
particulate and ionic silver would require additional separ-
ation techniques such as filtration or centrifugation. These
additional steps could result in retention of the ionic Ag-
macromolecule fraction to the filter or co-precipitation in cen-
trifugation due to a reaction of ionic Ag with macromolecules
in biological environments. This could be problematic in par-
ticular for this study where we deal with very low amounts of
translocated Ag. The use of two stable Ag isotopes could be
another promising approach to monitor the transformation of
AgNPs and dissolved Ag in biological systems by spICP-MS.58
However, using an enriched Ag isotope label in conjunction
with spICP-MS is not yet possible since only one isotope can
be detected by most ICP-MS instruments (some quadrupole
ICP-MS instruments are able to switch between two masses
during high time resolution measurements but quantitative
mass analysis is hardly possible with this technique because
important peak information is lost during the mass switching
time and signal intensities will suﬀer from spectral intensity
skew error59).
Comparison of translocation data with other studies
So far, potential AgNP translocation across the placenta has
only been investigated in pregnant rodents. The translocation
levels of Ag, measured by ICP-MS in the tissues of pups as the
total Ag mass concentrations and expressed as the percentages
of the administered dose, ranged from 0.008–0.009%,23
0.036%,11 0.085–0.147%,22 0.097%59 to 0.2–0.5%,24 while the
percentage of Ag accumulated in placental tissue varied
between 0.2%13,23 and 0.04–1.3%.24 In our study Ag transloca-
tion across the human placental barrier (0.015–0.062%, calcu-
lated as Ag mass fraction > and ≤25 nm) was in the same
range as those observed in rodent studies, while the percen-
tage of accumulated Ag in the placental tissue was about
10-times higher (12–16%). Although significant biological
diﬀerences in placental structure and function between
humans and rodents may contribute to the observed diﬀer-
ences, a direct comparison is challenging due to additional
physico-chemical diﬀerences in the NP types (size, surface
modifications), applied doses and routes of administration,
among others. For instance, the higher observed accumulation
of Ag in human placental tissue is most probably related to the
diﬀerent doses of AgNPs at the placental barrier. In in vivo
experiments where AgNPs were intravenously or orally dosed to
the rodents, NPs were not only distributed to the placenta but
also to other maternal organs, mainly the liver and kidneys.52
Therefore, biodistribution studies in rodents will still be
highly valuable to provide an estimate of the expected doses at
the placental barrier while human ex vivo placenta perfusion
studies can deliver important mechanistic insights on NP
translocation and accumulation at the intact human placental
barrier.
Conclusions
Diﬀerent surface properties of the selected AgNPs (neutral and
negatively charged coatings), which can aﬀect their solubility
and size through aggregation/agglomeration in PM, most prob-
ably influence diﬀerent translocation and accumulation behav-
ior of Ag. The results further demonstrate that particles
detected on the fetal side are not necessarily the result of
translocated pristine AgNPs, but could also be Ag precipitates
formed from dissolved Ag that crosses the placental barrier.
The detected Ag-containing particles in the fetal circulation,
which can result from translocation of intact AgNPs or from
re-precipitated Ag, were in the same concentration and size
range, which hampered the identification of any translocation
mechanism of AgNPs. Therefore, careful assessment of particle
dissolution and their possible re-precipitation under physio-
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logical conditions as well as the inclusion of ionic controls
should be an integral part of future translocation studies with
soluble NPs. Such measure would enable accurate interpret-
ation of the results and help to identify strategies towards pre-
vention of placental transfer of nanomaterials. Although trans-
location was low for both NP types the small amount of trans-
located ions/NPs may be suﬃcient to adversely aﬀect fetal
health, which should be carefully addressed in future studies.
Our study further demonstrates that spICP-MS is a promis-
ing technique to study the translocation of NPs. In contrast to
conventional ICP-MS, which was used in other published
studies dealing with translocation,23,24,60 spICP-MS addition-
ally provides information on the NP size distribution. This
allows studying NP changes like dissolution/aggregation and,
in this way, helps identifying mechanisms of transport.
Theoretically, spICP-MS can even distinguish between NPs and
the dissolved fraction of the analysed element if the size of the
studied NPs does not overlap with the minimum detectable size.
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